Search
Gadobenic acid
go.drugbank.com/drugs/DB00743ApprovedInvestigational[A263086] It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. … Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver.
Fluoride ion F-18
go.drugbank.com/drugs/DB09398ApprovedInvestigationalIts primary indication is for bone imaging. … It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection.
Ethambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisEfmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalIt is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It is suitable for all age groups. … Prophylactic treatment may dramatically improve the management of severe haemophilia A in the future by reducing joint bleeding and other hemorrhages that cause chronic pain and disability to patients
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996. … [A256272,A256277] UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 Enzyme InducersCarbocisteine
go.drugbank.com/drugs/DB04339ApprovedInvestigational[A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America. … [L32383] Several licenses for this drug were withdrawn following serious and fatal paradoxical effects after carbocisteine therapy in children; respiratory dress, dyspnea, and cough aggravation were
Lisavanbulin
go.drugbank.com/drugs/DB15224InvestigationalLisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
Everolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIt is currently used as an immunosuppressant to prevent rejection of organ transplants. … Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: Certican 0,1 mg - Tabletten zur Herstellung einer Suspension zum Einnehmen, Certican 0,25 mg - Tabletten zur Herstellung einer Suspension zum EinnehmenPipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnAmong the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. … It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors